HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early appearance and activation of natural killer cells in tumor-infiltrating lymphoid cells during tumor development.

Abstract
We investigated NK cell infiltration into tumor developing lesions at early stage of tumor development after intraperitoneal inoculation of 3LL lung carcinoma into syngeneic C57BL/6 mice. Natural killer (NK) cells, which were detected by anti-NK 1.1 monoclonal antibody (mAb), remarkably increased in number in tumor-developing lesions (peritoneal cavity) as early as day 3 after inoculation of 3LL. The tumor-infiltrating NK cells from 3LL-inoculated mice produced a high level of interferon-gamma by co-culture with 3LL and showed enhanced cytotoxic activities against both NK-sensitive (YAC-1) and NK-resistant (3LL and P815) tumors. Furthermore, mice depleted of NK cells by injection of anti-NK 1.1 mAb or anti-asialo GM1 antibody showed shorter survival times after intraperitoneal inoculation of 3LL when compared with control mice. These results suggest that NK cells infiltrate the tumor-developing lesion at an early stage and may participate in the early protection against tumors through production of a high amount of interferon-gamma and enhanced cytotoxicity at tumor-bearing sites.
AuthorsS Kurosawa, G Matsuzaki, M Harada, T Ando, K Nomoto
JournalEuropean journal of immunology (Eur J Immunol) Vol. 23 Issue 5 Pg. 1029-33 (May 1993) ISSN: 0014-2980 [Print] Germany
PMID8477798 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Surface
  • Interferon-gamma
Topics
  • Animals
  • Antigens, Surface (analysis)
  • Cytotoxicity, Immunologic
  • Female
  • Interferon-gamma (biosynthesis)
  • Killer Cells, Natural (immunology)
  • Lung Neoplasms (immunology)
  • Lymphocyte Activation
  • Lymphocytes, Tumor-Infiltrating (immunology)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred DBA
  • Neoplasms, Experimental (immunology, mortality)
  • T-Lymphocytes, Cytotoxic (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: